BACTAFORTE

This brand name is authorized in Nigeria.

Active ingredients

The drug BACTAFORTE contains one active pharmaceutical ingredient (API):

1	Ciprofloxacin UNII 4BA73M5E37 - CIPROFLOXACIN HYDROCHLORIDE
	Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
	Read more about Ciprofloxacin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100523	Eye ointment	BACTAFORTE EYE OINTMENT OINTMENT 0.3% 5GM	22 NF-PP-181037 BACTAFORTE EYE OINTMENT CIPROFLOXACIN OPHTHALMIC OINTMENT USP 0.3%W/W CIPROFLOXACIN OPHTHALMIC OINTMENT USP 0.3%W/W EXCIPIENTS sodium acetate, acetic acid, mannitol 4.6% Drugs Imported Products 5GM Prescription Only Medicine (POM) 11/10/2020 MANKIND LIFE-SCIENCES LIMITED, AGGREY ROAD, FEGGE ONITSHA ANAMBRA 659888884 mankindlifeltd2018@gmail.com Alpa Laboratories Limited, 33/2, A.B.Road, Pigdamber, 453-446,Indore (M.P.), India., India	28/09/2023
B4-0630	Tablet	BACTAFORTE TABLETS TAB 500 mg 1 X 10	BACTAFORTE TABLETS BACTAFORTE CIPROFLOXACIN HYDROCHLORIDE BP 500MG POM TABLETS 1 X 10 ANTIBIOTIC MANKIND LIFESCIENCES LTD NO. 2 AGGREY ROAD, FEGGE ONITSHA, ANAMBRA STATE ALPA LABORATORIES LTD. 33/2 A. B ROAD PIGDAMBER-453446, DIST: INDORE STATE (M.P), INDIA GMP-RBC; LR- SATIS; FEES- PAID; NP: NA 31/10/2018 R R R B4-0630	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA02	Ciprofloxacin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100523, B4-0630